Showing results (51-60 of 143) with videos related to

Sort By:
Pageof 15
Nature Chemical Biology|September 15, 2020
MYPT1 O-GlcNAc modification regulates sphingosine-1-phosphate mediated contractionNichole J Pedowitz, Anna R Batt, Narek Darabedian, et al.
RSC Chemical Biology|August 22, 2025
Achieving cell-type selectivity in metabolic oligosaccharide engineeringMichelle Marie B Helmeke, Rhianna L Haynie-Cion, Matthew R Pratt
Chemical Science|November 6, 2018
Asking more from metabolic oligosaccharide engineeringPierre-André Gilormini, Anna R Batt, Matthew R Pratt, et al.
Chembiochem : a European Journal of Chemical Biology|November 13, 2012
O-GlcNAc modification prevents peptide-dependent acceleration of α-synuclein aggregationNicholas P Marotta, Carli A Cherwien, Tharindumala Abeywardana, et al.
International Journal of Epidemiology|January 19, 2012
Increasing prevalence of HIV and syphilis but decreasing rate of self-reported unprotected anal intercourse among men who had sex with men in Harbin, China: results of five consecutive surveys from 2006 to 2010Kaili Wang, Hongmei Yan, Yanlin Liu, et al.
BMC Public Health|May 18, 2010
Knowledge and risk behaviors related to HIV/AIDS, and their association with information resource among men who have sex with men in Heilongjiang province, ChinaShengyuan Liu, Kaili Wang, Songpo Yao, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|August 30, 2021
Mechanism Prediction of Astragalus membranaceus against Cisplatin-Induced Kidney Damage by Network Pharmacology and Molecular DockingCongchao Jia, Xianchao Pan, Binyou Wang, et al.
BMC Bioinformatics|September 11, 2023
Prediction of the effects of small molecules on the gut microbiome using machine learning method integrating with optimal molecular featuresBinyou Wang, Jianmin Guo, Xiaofeng Liu, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|November 11, 2009
Association between the RAGE G82S polymorphism and Alzheimer's diseaseKeshen Li, Dawei Dai, Bin Zhao, et al.
Molecular Diversity|November 25, 2023
JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directionsXiaofeng Liu, Binyou Wang, Yuan Liu, et al.
Pageof 15